Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, […]

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer […]

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; […]

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer. Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt R., Silva F., Ward P., Whale A., Shuttleworth S. NCRI Meeting, Liverpool, UK, November 3, 2014, A114.

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/d Inhibitors for the Treatment of Cancer. Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt S., Silva F., Ward P., Whale A. Shuttleworth S. NCRI Meeting, Liverpool, UK, November 3, 2014, A143.

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer. Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr […]

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer. Shuttleworth S.J., Bone E.A; Cecil A.R.L., Colman L., Fulton R., Hill T.J., McCormick S., Nodes W.J., Rogers H., Silva F.A., Tomassi C.D., Whale A.D. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; […]